Suggested monitoring for patients with CVID*
Patients . | Type . | Interval . |
---|---|---|
All | Interval history, physical examination, height and weight | 12 months |
Complete blood counts: Hgb, Hct, white blood cells and differential, platelets, and chemistry panel, including liver and kidney functions; albumin | 12 months | |
serum IgG* | 6-12 months or with weight gain, pregnancy | |
Chest x-ray | Referral | |
Spirometry | 12 months | |
With lung disease | High-resolution chest computed tomography | 3-4 years or after change of therapy |
Complete lung functions with carbon monoxide diffusion | 12 months | |
With gastrointestinal complications | Upper and/or lower endoscopy | Intervals as required for optimum treatment |
With evidence of malabsorption, including loss of height (women in particular) | Bone density, evaluation of nutrients | As dictated by the therapy used |
Patients . | Type . | Interval . |
---|---|---|
All | Interval history, physical examination, height and weight | 12 months |
Complete blood counts: Hgb, Hct, white blood cells and differential, platelets, and chemistry panel, including liver and kidney functions; albumin | 12 months | |
serum IgG* | 6-12 months or with weight gain, pregnancy | |
Chest x-ray | Referral | |
Spirometry | 12 months | |
With lung disease | High-resolution chest computed tomography | 3-4 years or after change of therapy |
Complete lung functions with carbon monoxide diffusion | 12 months | |
With gastrointestinal complications | Upper and/or lower endoscopy | Intervals as required for optimum treatment |
With evidence of malabsorption, including loss of height (women in particular) | Bone density, evaluation of nutrients | As dictated by the therapy used |
CVID indicates common variable immune deficiency; Hct, hematocrit; Hgb, hemoglobin; IgA, immunoglobulin A; IgG, immunoglobulin G; and IgM; immunoglobulin M.
Consider adding also serum IgA or IgM if there is a question about the stability of the diagnosis or onset of other complications.